Innovating global regulatory frameworks for generative AI in medical devices is an urgent priority
Authors:
Top Cited Papers
Open Access
- 19 March 2026
- journal article
- review article
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1)
Abstract
The integration of generative AI (GenAI) and large language models (LLMs) in healthcare presents both unprecedented opportunities and challenges, necessitating innovative regulatory approaches. In this perspective, we discuss the risks of GenAI and LLM-based medical devices, the limitations of current medical device regulation frameworks when applied to GenAI or LLMs, and advocate for global collaboration in regulatory science research through engaging multidisciplinary expertise and focusing on the needs of diverse populations.Keywords
This publication has 70 references indexed in Scilit:
- Testing and Evaluation of Health Care Applications of Large Language ModelsJAMA, 2025
- FDA Perspective on the Regulation of Artificial Intelligence in Health Care and BiomedicineJAMA, 2025
- Low-Parameter Federated Learning with Large Language Models2024
- Use of Artificial Intelligence in Drug DevelopmentJAMA Network Open, 2024
- A Nationwide Network of Health AI Assurance LaboratoriesJAMA, 2024
- Use of Recalled Devices in New Device Authorizations Under the US Food and Drug Administration’s 510(k) Pathway and Risk of Subsequent RecallsJAMA, 2023
- Assessment of Adherence to Reporting Guidelines by Commonly Used Clinical Prediction Models From a Single VendorJAMA Network Open, 2022
- Algorithmovigilance—Advancing Methods to Analyze and Monitor Artificial Intelligence–Driven Health Care for Effectiveness and EquityJAMA Network Open, 2021
- From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patientsClinical Pharmacology & Therapeutics, 2014
- Pharmacovigilance: methods, recent developments and future perspectivesEuropean Journal of Clinical Pharmacology, 2008